The seventh batch of centralized drug procurement work was launched, and the competition pattern of 58 varieties was opened

 With the official announcement of the results of the sixth batch of national selection, the seventh batch of national selection has gradually entered the public eye
.
It is reported that recently, the seventh batch of national centralized procurement work has been launched
.
According to the "Notice on Submitting the Purchase Data Related to the Scope of the Seventh Batch of Nationally-Organized Centralized Drug Procurement" issued by the State-organized Drug Joint Procurement Office, which has been widely circulated in the industry recently, the seventh batch of centralized drug procurement has officially started, involving a total of 58 drugs.
Variety, 208 gauges
.
The drug treatment areas involved this time include antibiotics, tumors, diabetes, cardiovascular, nervous system and other fields
.
Among them, there are 7 varieties of antibacterial drugs.
In addition to the common cefixime, roxithromycin, and clindamycin phosphate, there are also 4 special-use antibacterial drugs, namely meropenem injection and micafungin injection.
, cefepime injection, tigecycline injection
.
According to the notice, the reporting volume will be officially launched on January 26, 2022, and the provinces will import the historical purchase volume data in 2021 for reference by medical institutions.
Submit data
.
Before 17:00 on February 25, all provinces need to complete the review of relevant drug procurement requirements
.
According to the industry, according to the regular progress of procurement with volume, after the procurement demand is reviewed and reported, it will enter the stages of publishing the centralized procurement documents, opening the bid, publishing the results of the proposed selection, confirming the official selection results and the landing time
.
The seventh batch of national centralized procurement involves a total of 198 enterprises (calculated by enterprise groups), including 29 foreign enterprises and 169 local enterprises
.
Among them, Qilu Pharmaceutical Group involves a total of 16 products (including 3 products from Qilu Hainan); Kelun involves 13 products (7 in Sichuan Kelun and 6 in Hunan Kelun); 11 in CSPC, including CSPC under CSPC 2 NBP, 8 CSPC Ouyi and 1 CSPC Yinhu; 11 CP departments, including 8 CP Tianqing Pharmaceutical Group, 2 Nanjing CP Tianqing Pharmaceutical and 1 Jiangsu CP Fenghai Pharmaceutical ; 10 in Yangtze River; 8 in Chengdu Bite (including 1 in Hainan); 7 in Fuan Group; 6 in Haosen
.
A total of 46 products are involved in 29 foreign companies, such as Pfizer, 5 products; Roche, 4; Novartis, 4; AstraZeneca, 3; Merck, 3
.
In addition, Sanofi, Xi'an Janssen and Japan's Sumitomo each involved 2 products
.
For the seventh batch of national mining, the industry said that it will return to chemical drugs as expected in the industry
.
Up to now, the national drug centralized procurement has carried out six batches and seven rounds (including "4+7 expansion centralized procurement"), covering 234 kinds of drugs, involving an amount of about 240 billion yuan
.
Except for the sixth batch of special centralized procurement for diabetes, the first five batches are all targeted at the field of chemical medicine, covering 218 varieties
.
Among the existing clinical drugs, there are about 490 kinds of chemical drugs, and more than half of them are not included in the scope of centralized procurement
.
According to the industry, from the current point of view, the national centralized procurement is gradually covering according to the progress of "collecting as much as possible", and chemical drugs are still the key areas of centralized procurement
.